28153991|t|Sex -Based Differences in Cardiometabolic Biomarkers
28153991|a|Few data are available comparing cardiovascular disease (CVD) biomarker profiles between women and men in the general population. We analyzed sex -based differences in multiple biomarkers reflecting distinct pathophysiological pathways, accounting for differences between women and men in CVD risk factors, body composition, and cardiac morphology. A cross-sectional analysis was performed using data from the Dallas Heart Study, a multiethnic population-based study. Associations between sex and 30 distinct biomarkers representative of 6 pathophysiological categories were evaluated using multivariable linear regression adjusting for age, race, traditional CVD risk factors, kidney function, insulin resistance, MRI and dual-energy x-ray absorptiometry measures of body composition and fat distribution, and left ventricular mass. After excluding participants with CVD, the study population included 3439 individuals, mean age 43 years, 56% women, and 52% black. Significant sex -based differences were seen in multiple categories of biomarkers, including lipids, adipokines, and biomarkers of inflammation, endothelial dysfunction, myocyte injury and stress, and kidney function. In fully adjusted models, women had higher levels of high-density lipoprotein cholesterol and high-density lipoprotein particle concentration, leptin, d-dimer, homoarginine, and N-terminal pro B-type natriuretic peptide, and lower levels of low-density lipoprotein cholesterol, adiponectin, lipoprotein - associated phospholipase A2 mass and activity, monocyte chemoattractant protein-1, soluble endothelial cell adhesion molecule, symmetrical dimethylarginine, asymmetrical dimethylarginine, high-sensitivity troponin T, and cystatin C. Biomarker profiles differ significantly between women and men in the general population. Sex differences were most apparent for biomarkers of adiposity, endothelial dysfunction, inflammatory cell recruitment, and cardiac stress and injury. Future studies are needed to characterize whether pathophysiological processes delineated by these biomarkers contribute to sex -based differences in the development and complications of CVD.
28153991	0	3	Sex	T032	C0079399
28153991	11	22	Differences	T080	C1705242
28153991	26	41	Cardiometabolic	T029	C3887460
28153991	42	52	Biomarkers	T201	C0005516
28153991	57	61	data	T078	C1511726
28153991	66	75	available	T169	C0470187
28153991	86	108	cardiovascular disease	T047	C0007222
28153991	110	113	CVD	T047	C0007222
28153991	115	124	biomarker	T201	C0005516
28153991	125	133	profiles	T169	C2003903
28153991	142	147	women	T098	C0043210
28153991	152	155	men	T098	C0025266
28153991	163	181	general population	T098	C0683971
28153991	186	194	analyzed	T062	C0936012
28153991	195	198	sex	T032	C0079399
28153991	206	217	differences	T080	C1705242
28153991	221	229	multiple	T081	C0439064
28153991	230	240	biomarkers	T201	C0005516
28153991	261	279	pathophysiological	T169	C0031847
28153991	280	288	pathways	T077	C1705987
28153991	305	316	differences	T080	C1705242
28153991	325	330	women	T098	C0043210
28153991	335	338	men	T098	C0025266
28153991	342	345	CVD	T047	C0007222
28153991	346	358	risk factors	T033	C0035648
28153991	360	376	body composition	T032	C0005885
28153991	382	389	cardiac	T023	C0018787
28153991	390	400	morphology	T080	C0332437
28153991	404	428	cross-sectional analysis	T062	C0010362
28153991	433	442	performed	T169	C0884358
28153991	449	453	data	T078	C1511726
28153991	463	481	Dallas Heart Study	T062	C0681876
28153991	485	519	multiethnic population-based study	T062	C0681876
28153991	521	533	Associations	T080	C0439849
28153991	542	545	sex	T032	C0079399
28153991	562	572	biomarkers	T201	C0005516
28153991	593	611	pathophysiological	T169	C0031847
28153991	612	622	categories	T170	C0683312
28153991	628	637	evaluated	T058	C0220825
28153991	644	657	multivariable	T081	C0439064
28153991	658	675	linear regression	T081	C0023733
28153991	676	685	adjusting	T169	C0456081
28153991	690	693	age	T032	C0001779
28153991	695	699	race	T098	C0034510
28153991	701	712	traditional	T169	C0443324
28153991	713	716	CVD	T047	C0007222
28153991	717	729	risk factors	T033	C0035648
28153991	731	746	kidney function	T042	C0232804
28153991	748	766	insulin resistance	T046	C0021655
28153991	768	771	MRI	T060	C0024485
28153991	776	808	dual-energy x-ray absorptiometry	T060	C1510486
28153991	809	817	measures	T081	C0079809
28153991	821	837	body composition	T032	C0005885
28153991	842	858	fat distribution	T033	C0424621
28153991	864	885	left ventricular mass	T033	C0455825
28153991	903	915	participants	T098	C0679646
28153991	921	924	CVD	T047	C0007222
28153991	930	946	study population	T098	C2348561
28153991	961	972	individuals	T098	C0027361
28153991	974	978	mean	T081	C0444504
28153991	979	982	age	T032	C0001779
28153991	986	991	years	T079	C0439234
28153991	997	1002	women	T098	C0043210
28153991	1012	1017	black	T098	C0005680
28153991	1019	1030	Significant	T078	C0750502
28153991	1031	1034	sex	T032	C0079399
28153991	1042	1053	differences	T080	C1705242
28153991	1067	1075	multiple	T081	C0439064
28153991	1076	1086	categories	T170	C0683312
28153991	1090	1100	biomarkers	T201	C0005516
28153991	1112	1118	lipids	T109	C0023779
28153991	1120	1130	adipokines	T116,T123	C1955907
28153991	1136	1146	biomarkers	T201	C0005516
28153991	1150	1162	inflammation	T046	C0021368
28153991	1164	1187	endothelial dysfunction	T047	C0856169
28153991	1189	1196	myocyte	T025	C0596981
28153991	1197	1203	injury	T049	C0599732
28153991	1208	1214	stress	T049	C1516360
28153991	1220	1235	kidney function	T042	C0232804
28153991	1246	1254	adjusted	T169	C0456081
28153991	1263	1268	women	T098	C0043210
28153991	1273	1279	higher	T080	C0205250
28153991	1280	1286	levels	T080	C0441889
28153991	1290	1326	high-density lipoprotein cholesterol	T109,T123	C0023822
28153991	1331	1364	high-density lipoprotein particle	T116,T123	C0023821
28153991	1365	1378	concentration	T081	C1446561
28153991	1380	1386	leptin	T116,T125	C0299583
28153991	1388	1395	d-dimer	T116,T123	C0060323
28153991	1397	1409	homoarginine	T116	C0019877
28153991	1415	1456	N-terminal pro B-type natriuretic peptide	T116,T123	C0754710
28153991	1462	1467	lower	T080	C0205251
28153991	1468	1474	levels	T080	C0441889
28153991	1478	1513	low-density lipoprotein cholesterol	T109,T123	C0023824
28153991	1515	1526	adiponectin	T116,T123	C0389071
28153991	1528	1539	lipoprotein	T116,T123	C0023820
28153991	1542	1552	associated	T080	C0332281
28153991	1553	1569	phospholipase A2	T116,T126	C0031667
28153991	1579	1587	activity	T044	C0243102
28153991	1589	1623	monocyte chemoattractant protein-1	T116,T129	C0128897
28153991	1625	1632	soluble	T080	C1948047
28153991	1633	1667	endothelial cell adhesion molecule	T116,T123	C3253526
28153991	1669	1680	symmetrical	T033	C0332516
28153991	1681	1697	dimethylarginine	T116	C1453836
28153991	1699	1711	asymmetrical	T082	C0332514
28153991	1712	1728	dimethylarginine	T116	C1453836
28153991	1730	1746	high-sensitivity	T059	C1441604
28153991	1747	1757	troponin T	T116,T123	C0077404
28153991	1763	1773	cystatin C	T116,T121	C0071744
28153991	1775	1784	Biomarker	T201	C0005516
28153991	1785	1793	profiles	T169	C2003903
28153991	1823	1828	women	T098	C0043210
28153991	1833	1836	men	T098	C0025266
28153991	1844	1862	general population	T098	C0683971
28153991	1864	1867	Sex	T032	C0079399
28153991	1868	1879	differences	T080	C1705242
28153991	1890	1898	apparent	T078	C0750489
28153991	1903	1913	biomarkers	T201	C0005516
28153991	1917	1926	adiposity	T032	C1563743
28153991	1928	1951	endothelial dysfunction	T047	C0856169
28153991	1953	1982	inflammatory cell recruitment	T033	C0243095
28153991	1988	2002	cardiac stress	T033	C2317276
28153991	2007	2013	injury	T037	C0018805
28153991	2065	2083	pathophysiological	T169	C0031847
28153991	2084	2093	processes	T067	C1522240
28153991	2114	2124	biomarkers	T201	C0005516
28153991	2139	2142	sex	T032	C0079399
28153991	2150	2161	differences	T080	C1705242
28153991	2169	2180	development	T169	C1527148
28153991	2185	2198	complications	T046	C0009566
28153991	2202	2205	CVD	T047	C0007222